Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Clinical Trial for the Treatment of Postnatal Depression
Brief Summary: A randomized clinical trial was carried out at primary care level in Santiago, Chile to investigate a combined treatment for women suffering post-natal depression and preventing the adverse consequences of this illness on infant's growth and development.


Options:
A: Inclusion Criteria:

* Primary DSM-IV diagnosis of major depressive disorder by clinical interview
* Score of greater than 12 on HAM-D
* Delivery of an infant within the 12 months prior to study entry
* Able to speak and read English sufficiently to complete the study procedures
* Willing to use effective birth control methods throughout the study

Exclusion Criteria:

* Woman whose infant has died prior to study entry
* Current or past diagnosis of bipolar disorder, schizophrenia or other psychotic disorder;
* Diagnosis of alcohol or drug abuse or dependence (except nicotine) or anorexia in the past year;
* Psychotic symptoms;
* Acute suicidal or homicidal risks;
* Women who have been on an antidepressant for more than 14 days prior to consent, (if less than 14 days and willing to taper off, will be eligible to continue once tapered off);
* Women on daily anxiolytic medication (i.e. benzodiazepine, buspirone) or daily psychoactive herbal preparation (St. John's Wort or Fish Oil) (if willing to discontinue these substances may be eligible once they have been tapered off);
* Medications taken PRN over the listed dose and frequency (women will still be eligible if they take: Lunesta/Eszopiclone 3 mg or less, up to 3 nights a week, Ambien/Zolpidem 5mg or less, Ambien CR 6.25 mg or less, up to 3 nights a week, Lorazepam or equivalent benzodiazepine dose: 0.5 mg up to 3 nights a week, Sonata/Zaleplon: 5 mg or less, up to 3 nights a week, Rozerem/Ramelteon: 8 mg or less, up to 3 nights a week);
* If they take antidepressants PRN for insomnia (eg: Desyrel/Trazodone, Elavil/Amitriptyline, Remeron/Mirtazapine;
* Ongoing concurrent psychotherapeutic treatment or psychotherapeutic treatment within the last month;
* Psychiatric symptoms requiring specialized psychiatric treatment;
* Significant medical disorder that would make sertraline treatment contra-indicated,
* Previous trial of IPT therapy with a certified IPT therapist or an adequate trial of sertraline (i.e. at least 8 weeks of at least 100 mg daily of sertraline).
B: Inclusion Criteria:

* 4-6 weeks postpartum
* English-speaking
* Score of at least 10 on the Edinburgh Postnatal Depression Scale

Exclusion Criteria:

* DSM-IV diagnosis of bipolar disorder or psychotic episode
* Active substance abuse within 6 months prior to study entry
* Has not received obstetrical care
* History of a suicide attempt within 6 months of study entry
C: Inclusion Criteria:

1. Women 18- 45 y.o.
2. SCID-DSM-IV diagnosis of major depression, mild to moderate severity
3. Understanding of Hebrew
4. Willing to sign the informed consent
5. Lactating women will be included after a thorough explanation of current knowledge of sertraline and lactation.

Exclusion Criteria:

1. Severe major depression (MADRS \> 30)
2. Suicidal ideation (MADRS item 10 score of \> 5)
3. Psychotic symptoms or aggressive thoughts toward the baby.
4. Current treatment with antidepressant medication
5. Physical illness explaining depressive symptoms (e.g. hypothyroidism, neurological disease, severe anemia, renal failure etc.)
6. Alcoholism or drug abuse and dependence
7. Bipolar Disorder
8. Past severe side effects to SSRIs
D: Inclusion Criteria:

* Mothers meeting criteria for current DSM-IV major depression were eligible.

Exclusion Criteria:

* who had received any form of treatment for their depression during their current postnatal period,
* those who were pregnant,
* with psychotic symptoms,
* serious suicidal risk,
* history of mania,
* alcohol or drug abuse

Answer: D